Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients
Objective. To assess the efficacy and tolerability of the association sibutramine (10–20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were assessed...
Main Authors: | Alfredo Halpern, Renata B. Pepe, Ana Paola Monegaglia, Mônica Beyruti, Maria Edna de Melo, Marcio C. Mancini |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | Journal of Obesity |
Online Access: | http://dx.doi.org/10.1155/2010/602537 |
Similar Items
-
Orlistat in the prevention of diabetes in the obese patient
by: Marcio C Mancini, et al.
Published: (2008-04-01) -
Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study
by: Panagiotis Anagnostis, et al.
Published: (2012-01-01) -
A survey on clinical effectiveness of orlistat compared to sibutramine, lorcaserin, metformin and placebo on weight loss in obese people: a network meta-analysis
by: Somaye Fatahi, et al.
Published: (2018-09-01) -
Obesity management: Update on orlistat
by: Belinda S Drew, et al.
Published: (2008-01-01) -
Sibutramine versus Metformin: assessment of anthropometric, lipid and glycemic parameters in obese and overweight high-risk patients
by: Camilo Molino Guidoni, et al.
Published: (2012-01-01)